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Many G-protein-coupled receptors (GPCRs) are expressed on the plasma membrane as 
dimers. Since drug binding data are currently fitted using equations developed for 
monomeric receptors, the interpretation of the pharmacological data are equivocal in 
many cases. As reported here, GPCR dimer models account for changes in competition 
curve shape as a function of the radioligand concentration used, something that cannot 
be explained by monomeric receptor models. Macroscopic equilibrium dissociation 
constants for the agonist and homotropic cooperativity index reflecting the 
intramolecular communication within the dopamine D1 or adenosine A2A receptor 
homodimer as well as hybrid equilibrium dissociation constant, which reflects the 
antagonist/agonist modulation may be calculated by fitting binding data from 
antagonist/agonist competition experiments to equations developed from dimer receptor 
models. Comparing fitting the data by assuming a classical monomeric receptor model 
or a dimer model, it is shown that dimer receptor models provide more clues useful in 
drug discovery than monomer-based models.
Keywords: Adenosine receptors, dopamine receptors, competition curves, two-state 
dimer receptor model, equilibrium dissociation constants, cooperativity














































































Knowing the binding affinity of newly developed drugs is a mandatory step for 
the pharmacological characterization of drugs acting on their targets. Quite often, 
displaying data on the binding of natural or synthetic neurotransmitters or 
neuromodulators to specific G-protein-coupled receptors (GPCRs) gives concave 
upward Scatchard plots [1] rather than a straight line, reflecting cooperativity in the 
binding. The approach most often used to deal with such type of data is based on two 
assumptions: one is that receptors are monomeric and another is that two different 
(monomeric) receptor forms are capable of binding the ligand but with different 
affinities. In its most commonly used form, it is assumed that one population of 
receptors is coupled to a G protein and displays high affinity, whereas another is 
uncoupled from any G protein and displays low-affinity binding for agonists. These two 
different forms of the receptor, which have different affinities for agonists (KDH and 
KDL), have to be independent and cannot be in equilibrium. For this reason, the model is 
usually known as the two-independent-site model [2]. The two-independent-site 
approach has been very useful and has been often used in cases of complex binding. 
However this approach is meaningful only if the two states of the receptor with high and 
low affinity for ligands are totally independent, i.e. they are not in equilibrium and they 
cannot be converted into each other. This is possible in artificial sytems such as that 
described by Whorton et al., [3] but there is evidence that it is not likely to happen in 
cells.
Given the predominance of heptaspanning membrane receptors as dimers (see 
[4-15] for an extensive review), the interpretation of complex binding using a receptor 
dimer model might be more straightforward. In this case positive or negative 
cooperativity is naturally explained by assuming, like in the case of the enzymes, that 













































































binding of the first ligand to the dimer modifies the equilibrium parameters of binding 
of the second ligand molecule to the dimer. Based on the above considerations dimer 
receptor models have been developed by some authors [1,16-19]. Dimer models are able 
to explain both concave upward and concave downward Scatchard plots that likely 
express, respectively, negative and positive cooperativity. One relevant feature of the 
two-state dimer model reported by Franco et al., [1,17] is the possibility of calculating 
the degree of cooperativity among protomers.
Although from a theoretical point of view it seems obvious that dimer models 
will be of election for fitting binding data to a great number of GPCRs, dimer models, 
as originally described [1, 17, 18], provided equations including microscopic binding 
constants that did not give practical information about how to determine the 
macroscopic constants values. The recent development by Casadó et al. [19] describes a 
macroscopic analysis that is readily applicable in day to day receptor pharmacological 
data management. In this paper D1 dopamine and A2A adenosine receptors were selected 
as a model due to their well established ability to form homodimers [20-23]. Ligand 
binding data from antagonist/agonist competition experiments were fitted to equations 
developed from the two-independent-site model for monomeric receptors or from the 
two-state dimer receptor model. The macroscopic equilibrium dissociation constants for 
the agonist, the dimer cooperativity index reflecting the molecular communication 
within the dimer for the agonist binding and a hybrid equilibrium 
radioligand/competitor dissociation constant, which reflects the antagonist/agonist 
modulation in competition experiments, were calculated. These parameters may help in 
the criteria for selecting drugs under development. 













































































2. Materials and methods
2.1. Membrane preparation and protein determination 
Membrane suspensions from sheep brain striatum were processed as described 
previously [2, 24]. Tissue was disrupted with a Polytron homogenizer (PTA 20 TS 
rotor, setting 3; Kinematica, Basel, Switzerland) for three 5 s-periods in 10 volumes of 
50 mM Tris-HCl buffer, pH 7.4 containing a proteinase inhibitor cocktail (Sigma, St. 
Louis, MO, USA). Cell debris were eliminated and membranes were obtained by 
centrifugation at 105,000 g (40 min, 4°C), and the pellet was resuspended and 
recentrifuged under the same conditions. The pellet was stored at -80°C and was 
washed once more as described above and resuspended in 50 mM Tris-HCl buffer for 
immediate use. Protein was quantified by the bicinchoninic acid method (Pierce 
Chemical Co., Rockford, IL, USA) using bovine serum albumin dilutions as standard.
2.2. Radioligand binding experiments
Membrane suspensions (0.25-0.5 mg of protein/ml) were incubated 2 h at 25ºC 
in 50 mM Tris-HCl buffer, pH 7.4, containing 10 mM MgCl2 with the indicated free 
concentration of the dopamine D1 receptor antagonist [
3H]SCH 23390 (NEN Perkin 
Elmer, Wellesley, MA, USA) or with 0.7 or 3.6 nM free concentration of the adenosine 
A2A receptor antagonist [
3H]ZM 241385 (American Radiolabeled Chemicals, St. Louis, 
MO, USA) and increasing concentrations of, respectively, the D1 receptor agonist SKF 
81297 or SKF 38393 (triplicates of 13 different concentrations from 0.1 nM to 50 μM; 
Tocris, Ellisville, MO, USA) or increasing concentrations of the A2A receptor agonist 













































































CGS 21680 (triplicates of 13 different concentrations from 0.1 nM to 50 μM; Tocris,
Ellisville, MO, USA) respectively. Nonspecific binding was determined in the presence 
of 10 μM SCH 23390 or 10 μM ZM 241385 (Tocris, Ellisville, MO, USA) and 
confirmed that the value was the same as calculated by extrapolation of the competition 
curves. Free and membrane-bound ligand were separated by rapid filtration of 500 μl 
aliquots in a cell harvester (Brandel, Gaithersburg, MD, USA) through Whatman GF/C 
filters embedded in 0.3% polyethylenimine that were subsequently washed for 5 s with 
5 ml of ice-cold Tris-HCl buffer. The filters were incubated with 10 ml of Ecoscint H 
scintillation cocktail (National Diagnostics, Atlanta, GA, USA) overnight at room 
temperature and radioactivity counts were determined using a Tri-Carb 1600 
scintillation counter (PerkinElmer, Boston, MA, USA) with an efficiency of 62% [24]. 
2.3. Binding data analysis
Radioligand competition curves were analyzed by nonlinear regression using the 
commercial Grafit curve-fitting software (Erithacus Software, Surrey, UK), by fitting 
the specific binding data to the two-state dimer receptor model [1, 17]. To calculate the 
macroscopic equilibrium dissociation constants involved in the binding of the agonist, 
the following equation for a competition binding experiment deduced by Casadó et al. 
[19] was considered:
Abound = (KDA2 A + 2A
2 + KDA2 A B / KDAB) RT / (KDA1 KDA2 + KDA2 A + A
2
+ KDA2 A B/ KDAB + K DA1 KDA2 B / KDB1  + KDA1 KDA2 B
2 / (KDB1 KDB2)) eq. 1
where A represents the radioligand (the dopamine D1 receptor antagonist [
3H]SCH 
23390 or the adenosine A2A receptor antagonist [
3H]ZM 241385) concentration, RT is 
the total amount of receptor dimers and KDA1 and KDA2 are the macroscopic dissociation 













































































constants describing the binding of the first and the second radioligand molecule (A) to 
the dimeric receptor; B represents the assayed competing compound (the dopamine D1
receptor agonists SKF 81297 and SKF 38393 or the adenosine receptor agonist CGS 
21680) concentration and KDB1 and KDB2 are, respectively, the equilibrium dissociation 
constants of the first and second binding of B; KDAB can be described as a hybrid 
equilibrium radioligand/competitor dissociation constant, which is the dissociation 
constant of B binding to a receptor dimer semi-occupied by A. 
Since the radioligand A (the antagonist [3H]SCH 23390 or the antagonist 
[3H]ZM 241385) showed non-cooperative behaviour ([1, 19]  and results not shown), 
eq. (1) was simplified to eq. (2) due to the fact that  KDA2 = 4KDA1 (see [19]):
Abound = (4KDA1 A + 2A
2 + 4KDA1 A B / KDAB) RT / (4KDA1
2 + 4KDA1 A + A
2
+ 4KDA1 A B / KDAB + 4KDA1
2 B / KDB1 + 4KDA1
2 B2 / (KDB1 KDB2)) eq. 2
The dimer cooperativity index for the competing ligand B (the agonists SKF 
81297 or SKF 38393 for dopamine D1 receptors, or the agonist CGS 21680 for 
adenosine A2A receptors) was calculated as (see [19]):
DCB = log (4KDB1 / KDB2) eq. 3
A direct calculation of the concentration of B providing half saturation (B50) was 
obtained according to Casadó et al., [19]:
B50 = (KDB1 KDB2)
1/2 eq. 4













































































In the experimental conditions when both the radioligand A (the antagonist 
[3H]SCH 23390 or the antagonist [3H]ZM 241385) and the competitor B (the agonists 
SKF 81297 and CGS21680)  show non-cooperativity, it results that KDA2 = 4KDA1 and 
KDB2 = 4KDB1, and eq. (1) was simplified to:
Abound = (4KDA1 A + 2A
2 + 4KDA1 A B / KDAB) RT / (4KDA1
2 + 4KDA1 A + A
2
+ 4KDA1 A B / KDAB + 4KDA1
2 B / KDB1  + KDA1
2 B2 / KDB1
2) eq. 5
For comparison, data were also fitted to the classical one-site receptor model 
when monophasic competition curves were observed and to the classical two-
independent-site receptor models when biphasic competition curves were obtained, 
using respectively the equations:
Abound = R IC50 / (IC50 + B) eq. 6
Abound = RH IC50H / (IC50H + B) + RL IC50L / (IC50L + B) eq. 7
where R, RH and RL are the specific binding in the absence of competing ligand. IC50, 
IC50H and IC50L of the B compound are related with the respective equilibrium 
dissociation constants KD, KDH and KDL according with Cheng and Prusoff [25] 
equation: 
IC50H = KDH (1 + A / KDA) IC50L = KDL (1 + A / KDA) eq. 8













































































Goodness of fit was tested according to reduced χ2 value given by the nonlinear 
regresion program. The test of significance for two different model population variances 
was based upon the F-distribution (see [2] for details). Using this F test, a probability 
greater than 95% (p<0.05) was considered the criterion to select a more complex model 
(cooperativity in eq. 2 or two-sites in eq. 7) over the simplest one (non-cooperativity in 
eq. 5 or one-site in eq. 6). In all cases, a probability of less than 70% (p>0.30) resulted 
when one model was not significantly better than the other. Results are given as 
parameter values ± S.E.M. of three independent experiments.














































































3.1. Comparison of macroscopic dissociation constants for the agonist SKF 81297 
binding to D1 dopamine receptor calculated by using the two-state dimer receptor 
model or the two-independent-site model for monomeric receptors.
Competition experiments were performed with a constant concentration of 
radiolabelled dopamine D1 receptor antagonist [
3H]SCH 23390 (1.8 nM or 0.8 nM) and 
increasing concentrations of dopamine D1 receptor agonist, SKF 81297, as described in 
Materials and Methods. Binding data (Figures 1 and 2) were fitted to equations derived 
from the two-state dimer receptor model [1, 19]. [3H]SCH 23390 binding to D1 receptor 
showed linear Scatchard plots [19]; thus, binding data were fitted to eq. (2) and (5) (see 
Materials and Methods) introducing the previously reported KDA1 value of 0.47 nM for 
the non-cooperative [3H]SCH 23390 binding to D1 receptor [19]. At 1.8 nM [
3H]SCH 
23390 a biphasic curve was obtained (Figure 1) and the fit of the binding data to the eq. 
(2) was not better than the fit to eq. (5). In fact, binding data from competition curve fit 
enough well to the two-state dimer receptor model without cooperativity in SKF 81297
binding (solid line in Figure 1) and the calculated values for parameters RT, KDB1 and 
the hybrid parameter, KDAB (see Methods), are shown in Table 1. This hybrid parameter, 
KDAB, which reflects an agonist-antagonist modulation, is instrumental to explain a 
biphasic curve by means of a non-cooperative binding (see Discussion). For 
comparative purposes, binding data were also fitted assuming one- or two-sites of 
monomeric receptors. Data from the biphasic curve was poorly handled by assuming 
one (monomeric) site and, therefore, binding data fit well to two sites (Figure 1). 
Assuming momeric receptors monophasic curves are only explained by binding to one 
site whereas biphasic curves require two independent centers with significantly different 
equilibrium constant values. Fitting data to eq. (7) and (8) the two equilibrium constants 













































































were obtained (Table 1): RH (high affinity) and RL (low affinity), being approximately 
35:65 the proportion of receptors in high affinity (usually considered coupled to G 
proteins) versus those in low afinity (usually considered uncoupled to G proteins). At 
0.8 nM [3H]SCH 23390 (Figure 2) a monophasic competition curve was obtained. 
Binding data were fitted assuming the two-state dimer receptor model and also 
assuming one (eq. 6) or two (eq. 7) (monomeric) sites. Data shown in Figure 2 fitted 
enough well to a dimer without cooperativity (eq. 5) and to one (monomeric) site (eq. 6) 
and no improvement was found by data fitting to a more complex equation (eq. 7). It 
should be noted that the parameters deduced using the two-state dimer receptor model 
(Table 1) are not significantly different from the ones obtained using a higher 
radioligand concentration, indicating that the two-state dimer receptor model is robustly 
giving consistent parameter values independently of the radioligand concentration used. 
On the contrary, parameter values calculated assuming monomers differ in the two 
experimental conditions (high versus low radioligand concentration; see Table 1)
3.2. Useful new pharmacological parameters can be obtained from competition curves 
considering the two-state dimer receptor model.
From the two-state dimer receptor model new parameters can be obtained that 
provide relevant and useful information. One of such parameters is the cooperative 
index (DC). DC would be a measure of the orthosteric dissociation equilibrium constant 
value modifications occurring when a protomer senses the binding of the same ligand 
molecule to the partner protomer (in a dimer). For the agonist SKF 81297 binding to D1
receptors the DC value was zero (DCB in Table 1). A 0 value indicates that there is not 
any sign of cooperativity, i.e. that the SKF 81297 binding to one protomer in the dimer 
did not modify the affinity for SKF 81297 in the other protomer in the dimer. 













































































Another pharmacological parameter is the hybrid equilibrium dissociation 
constant (KDAB in eqs. 1, 2 and 5). The KDAB constant corresponds to the equilibrium 
dissociation constant for the competing ligand (B) when the dimer is semi-occupied by 
the radioligand (A). The value of KDAB in Table 1 is the dissociation constant of the 
agonist SKF 81297 binding to a receptor dimer semi-occupied by the antagonist 
[3H]SCH 23390. When KDAB = 2 KDB1 the binding of the radioligand to one protomer in 
the dimer does not modify the binding of the competing ligand to the other empty 
protomer in the dimer. In contrast, values of KDAB 2 KDB1 or KDAB2 KDB1 indicate, 
respectively, a positive or negative effect exerted by the radioligand on the competitor 
binding to the empty protomer (see Supplemental Material for details). This effect is 
exerted by ligand binding to one orthosteric site over the binding of a different ligand to 
the second orthosteric site in the dimer. This means that it is possible to measure 
whether the antagonist [3H]SCH 23390 binding to a empty receptor dimer modulates 
(negatively or positively) the agonist SKF 81297 binding to the other subunit in the
dimer. According to this, we here introduce a new parameter, "the dimer 
radioligand/competitor modulation index” (DAB), ("SCH 23390/SKF 81297 modulation 
index", see Table 1) which is defined as DAB = log (2 KDB1/KDAB). The way as the index 
is defined is such that its value is "0" when the radioligand binding to a protomer does 
not affect the competitor binding to the empty protomer in the dimer. Positive or 
negative values of DAB indicate that the presence of a radioligand bound to a increases 
or decreases, respectively, the competitor affinity for binding to the empty protomer in 
the dimer. The DAB = 0.6 for D1 dopamine receptor described in Table 1 indicates 
positive modulation between [3H]SCH 23390 and SKF 81297 binding.
Furthermore, from a pharmacological point of view, one interesting aspect of the 
two-state dimer receptor model is that it allows a direct calculation of the concentration 













































































providing half saturation for the tested compound (B50) that corresponds exactly to the 
concentration of agonist providing half saturation for the competing ligand, independent 
of the biphasic or monophasic nature of the competition curve or of the radioligand 
concentration (see Table 1).
3.3. Pharmacological parameters for the agonist SKF 38393 binding to D1 dopamine 
receptor calculated assuming dimers or monomers.
Experiments at two different concentrations of the dopamine D1 receptor 
antagonist [3H]SCH 23390 (0.11 and 0.67 nM) were performed and the competition 
curve obtained increasing concentrations of the dopamine D1 receptor agonist, SKF 
38393, was biphasic in both cases (Figure 3). Considering the two-state dimer receptor 
model, the fit of the binding data to eq. (2) was better than the fit to eq. (5). In fact, 
binding data fit well to the two-state dimer receptor model with cooperativity on the 
binding of SKF 38393 (solid line in Figure 3A and B) and the calculated parameters
values are shown in Table 2. Binding data were also fitted considering the one-site or 
two-independent-site monomeric receptor models. As it is shown in Figure 3, binding 
data fit well to two (monomeric) sites or to a dimer. By fitting data to eq. (7) and (8), 
KDH (high affinity) and KDL (low affinity) equilibrium constants were obtained (Table 
2). The parameters deduced using the two-state dimer receptor model are not 
significantly different using high or low radioligand concentrations, indicating that the 
two-state dimer receptor model is robust. On the contrary, parameter values for the high 
affinity state calculated assuming monomers differ in the two experimental conditions 
(high versus low radioligand concentration; see Table 2)













































































3.4. Pharmacological parameters for the agonist CGS 21680 binding to A2A adenosine 
receptor calculated assuming dimers or monomers.
Competition experiments were performed at two different constant 
concentrations of the radiolabelled adenosine A2A receptor antagonist, [
3H]ZM-241385 
(0.7 or 3.6 nM), and increasing concentrations of the adenosine A2A receptor agonist, 
CGS 21680. Binding data (Figure 4) were fitted to equations derived from the two-state 
dimer receptor model taking into account that [3H]ZM-241385 binding to adenosine 
A2A receptor shows linear Scatchard plots (results not shown). Therefore binding data 
must be fitted to eq. (2) and (5) by introducing the previously obtained KDA1 value of 
0.66 nM. For both radioligand concentrations used, the fit of the binding data to the eq. 
(2) was not better than the fit to eq. (5) thus indicating that binding of CGS21680 is 
non-cooperative (solid line in Figure 4A and B). Binding data were also fitted 
considering one or two sites. As it is shown in Figure 4A, at the higher concentration 
binding data fit better to two than to one (monomeric) (Figure 4A). In contrast, as 
shown in Figure 4B, data obtained at low radioligand concentration fit fairly well to the 
equations describind binding to one site l (eq. 6) and no improvement was found using 
the equation describing binding to two independent monomeric sites (eq. 7). The 
parameters deduced appear in Table 3.














































































4.1. Useful new pharmacological parameters can be obtained from competition curves 
considering the two-state dimer receptor model
One interesting aspect of the two-state dimer receptor model is that the values of 
the different parameters can provide more information than those from the two-
independent-site model. Using the two-state dimer receptor model the number of 
receptor dimers (RT), which correspond to half of maximum binding, are directly 
obtained without any a priori assumption about coupling or uncoupling to G proteins or 
else.  The two macroscopic constants (KDB1 and KDB2) correspond to the ligand binding 
to an empty dimer and to a semi-occupied dimer, respectively. Comparison of values in 
Table 1 to 3 shows that the macroscopic constants, KDB1 and KDB2, are different from 
the KDH and KDL obtained assuming the classical monomeric models. It should be noted 
that the difference is not only numerical but also conceptual; in fact, the meaning of 
KDB1 and KDB2 versus KDH and KDL is quite different and for a dimeric GPCR it is more 
straightforward to use KDB1 and KDB2.
For receptor homodimers, the binding of the first ligand to the orthosteric site in 
the dimer can modify the equilibrium parameters of the second ligand molecule binding 
to the other orthosteric site in the dimer and, in this case, cooperativity naturally comes 
from homotropic (the same ligand is modulating) ligand-driven intramolecular 
conformational changes in the dimer. In fact, one of the main advantages provided by 
the two-state dimer receptor model is the calculation of a cooperative index (DC). DC
would be a measure of the orthosteric dissociation equilibrium constant value 
modifications occurring when a protomer senses the binding of the same ligand 













































































molecule to the partner protomer (in a dimer). Comparing the SKF 81297 and the SKF 
38393 binding to dopamine D1 receptors it was demonstrated that the homotropic 
cooperativity appearance depends on the characteristics of the ligand being used. In fact, 
the partial agonist SKF 38393 displayed negative homotropic cooperativity (negative 
DCB value in Table 2). In contrast, for the full agonist, SKF 81297, binding to D1
receptors the DC value was zero (Table 1) indicating that there is not any sign of 
cooperativity, i.e. that the SKF 81297 binding to one protomer in the dimer did not 
modify the affinity for SKF 81297 in the other protomer in the dimer. One interesting 
aspect that requires attention is that biphasic competition curves are usually interpreted 
by dimer models as resulting from negative cooperativity. It would seem therefore 
paradoxical to obtain a biphasic curve for non-cooperative binding to a receptor dimer 
(see Figure 1 and table 1). But this is indeed possible due to the fact that the one 
orthosteric ligand may affect the binding of a different orthosteric ligand. The hybrid 
equilibrium dissociation constant (KDAB) is a measure of this ligand-ligand modulation. 
In fact, the KDAB constant corresponds to the equilibrium dissociation constant for the 
competing ligand (B) when the dimer is semi-occupied by the radioligand (A). This 
means that it is possible to measure, by the dimer radioligand/competitor modulation 
index (DAB), whether the antagonist [
3H]SCH 23390 binding to a empty receptor dimer 
modulates (negatively or positively) the agonist SKF 81297 binding to the other subunit 
in the dimer. When this type of modulation occurs, the competition curve shape depends 
not only on the homotropic cooperativity of the competitor (DCB) but also on the 
radioligand/competitor modulation. This new concept of modulation between two 
different orthosteric ligands, i.e., antagonist/agonist, proves to be very useful when 
analysing competition experiments. The DAB for D1 dopamine receptor described in 
Table 1 indicates positive modulation between [3H]SCH 23390 and SKF 81297 binding 













































































that induces the appearance of a biphasic competition curve even in the absence of any 
homotropic cooperativity. This phenomenon was further illustrated by the simulation 
curves displayed in Figure 5. Assuming that there is a marked positive modulation 
between the radioligand and the competing ligand, the two-state dimer receptor model 
predicts the evolution from biphasic competition curves to monophasic ones when 
decreasing the radioligand concentration (Figure 5). This was proved by competition 
experiments with a relatively low radioligand antagonist concentration to diminish the 
effect of antagonist/agonist modulation according to the prediction shown in Figure 5. 
For the low radioligand concentration, the parameters deduced for SKF 81297 binding 
to D1 dopamine receptor, using the two-state dimer receptor model (Table 1) are not 
significantly different from the ones obtained using higher radioligand concentration, 
indicating that the two-state dimer receptor model is robustly giving consistent 
parameter values independently of the radioligand concentration used. On the contrary, 
the parameters deduced from a monomer-based model differ in the two experimental 
conditions and, since this is not possible under a mechanistic point of view, this 
indicates that the monomer-based model is unable to explain the experimental results. 
One interesting feature arises when comparing values of pharmacological parameters 
obtained using the two-state dimer receptor model for the two different radioligand 
concentrations used (Table 1, Figures 1 and 2). In fact, the experimental results 
demonstrate that the antagonist/agonist modulation induces, at high antagonist 
concentrations, the appearance of a biphasic competition curve, independent of the 
existence or not of competitor homotropic cooperativity as predicted by the two-state 
dimer receptor model. 
To extend this conclusion beyond dopamine receptors, agonist vs antagonist 
competition experiments of binding to adenosine A2A receptors were performed at two 













































































different radioligand concentrations (Figure 4). The parameters deduced using the two-
state dimer receptor model, but not those deduced from a monomer-based model (Table 
3), were similar at low or high radioligand concentrations, indicating that the two-state 
dimer receptor model is robustly giving consistent parameter values. For the agonist, 
CGS 21680, binding to adenosine A2A receptors the DCB value was zero (Table 3) 
indicating that there is not any sign of cooperativity, i.e. that the CGS 21680 binding to 
one protomer in the dimer did not modify the affinity for CGS 21680 binding to the 
other protomer in the dimer. This is another model system in which a biphasic curve 
results from non-cooperative binding to a receptor dimer (see Figure 1 and table 1). 
Again, this is feasible due to the fact that the one orthosteric ligand affects the binding 
of a different orthosteric ligand, something that may be quantitated in the form of a 
hybrid equilibrium dissociation constant (KDAB). A radioligand/competitor modulation 
index (DAB) of approximately 0.4 for A2A receptor was calculated indicating positive 
modulation between [3H]ZM-241385 and CGS 21680 binding that induces the 
appearance of a biphasic competition curve even in the absence of any homotropic 
cooperativity. Collectively, the results indicate that the two-state dimer receptor model 
is a suitable model to handle binding data to GPCRs.
4.2. Monomeric models cannot handle changes in the proportion of low- and high-
affinity sites induced by varying the radioligand concentration
Since the two-independent-site model assumes that the states are independent 
and not modified by the ligands, the significant changes in the proportion of low- and 
high-affinity sites induced by varying the radioligand concentration (see Tables 1 to 3)
cannot be explained using such a model. At low radioligand concentration the 
proportion of receptors in high affinity (usually considered coupled to G proteins) 













































































versus those in low afinity (usually considered uncoupled to G proteins) was 0:100 for 
SKF 81297 or 37:63 for SKF 38393 binding to dopamine D1 receptors whereas they 
were 35:65 and 26:74, respectively, at the higher radioligand concentration. For the 
CGS 21860 binding to adenosine A2A receptors this proportion at low radioligand 
concentration was 0:100 whereas it was 58:42 at the higher radioligand concentration. 
These data are inconsistent, which proves that the monomeric model cannot handle such 
experimental data. Using the two-state dimer receptor model the number of receptor 
dimers (RT), which correspond to half of maximum binding, are directly obtained 
without any a priori assumption about coupling or uncoupling to G proteins or else. 
4.3. Can high and low affinity constants to receptor dimers be calculated from 
competition experiments?
Scientists usually use the two-independent-site monomeric model to fit 
pharmacological data and drug screening is usually performed by means of radioligand 
antagonist/drug competition curves from which high (KDH) and low (KDL) affinity 
(equilibrium) constants are calculated.
As described in this paper the meaning and in some cases (as for SKF81297 
binding to D1 dopamine receptors or CGS 21860 binding to A2A adenosine receptors) 
the existence of these two receptor affinity sites apparently depends upon the 
concentration of the radioligand. Moreover, it may happen that at relatively high 
radiolabelled antagonist concentrations, the percentage of receptors showing high 
affinity for the agonist is different from that obtained performing the experiment at 
relatively low radiolabelled antagonist concentration (Tables 1 to 3). Since the two-
independent-site model assumes that the states are independent and not modified by the 
ligands, changes in the proportion of low- and high-affinity sites induced by varying the 













































































radioligand concentration in a competition experiment cannot be explained using such a 
model. Furthermore, none of the reported monomer-based models are able to explain 
the above described results. In summary, one must be cautious when using classical 
(monomeric) models when trying to interpret biphasic competition curves. In sharp 
contrast, the two-state dimer receptor model predicts at low radioligand concentrations 
the “disappearance” of one affinity state (Tables 1 and 3) as a consequence of a 
radioligand/competitor modulation. This indeed constitutes one of the most interesting 
messages provided herewith, i.e. that a direct translation of a biphasic competition curve 
into the existence of two affinity sites or into the existence of homotropic cooperativity 
of the competitor may not be correct.
At the two radiolabelled antagonist concentrations assayed, the macroscopic 
parameters, i.e. the equilibrium constants, obtained using the two-state dimer receptor 
model (Tables 1 to 3) are similar and are independent of the monophasic or the biphasic 
nature of the competition curve. This may be considered a proof of the usefulness of the 
model since the concentration of the radioligand should not modify the values of the 
parameters. Furthermore, from a pharmacological point of view, one interesting aspect 
of the two-state dimer receptor model is that it allows a direct calculation of the 
concentration providing half saturation for the tested compound (B50). As demonstrated 
here, the parameter, B50, is more suitable than the usually employed IC50 values for 
ordering the compounds according to their binding potency. For dopamine D1 receptor 
and adenosine A2A receptor  the B50 calculated using eq. (4) and reported in Tables 1 to 
3 corresponds to the concentration of agonist providing half saturation for the 
competing ligand, independent of the biphasic or monophasic nature of the competition 
curve or of the radioligand concentration. In contrast, the two IC50 values, obtained 
using the classical monomer-based receptor model, have an ambiguous meaning. IC50













































































values depend on the radioligand concentration and on the shape of the curve (Figure 2). 
Thus, is then evident that IC50 is not a useful parameter to use in cases of complex 
binding data. 
Taking all these data into consideration, the two-state dimer receptor model 
gives information of maximum binding (2 RT), of macroscopic dissociation constants 
and moreover, relevant information about the existence and quantification of 
homotropic cooperativity (DC) and radioligand/competitor affinity modulation (DAB) 
and a reliable B50 value for ordering compounds according to their binding potency. In 
cases in which homotropic cooperativity or radioligand/competitor interaction exists, 
the two-state dimer model is the model of election to calculate macroscopic dissociation 
constants. This is of particular importance for pharmacologists to overcome drawbacks 
derived from the use of classical monomeric receptor models to fit binding data.
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Figure 1. Competition experiments using a relatively high D1 receptor antagonist 
concentration versus increasing concentrations of the D1 receptor agonist SKF 
81297. Competition experiments of the D1 receptor antagonist [
3H]SCH 23390 (1.8 nM) 
versus increasing concentrations of the D1 receptor agonist SKF 81297 (0.1 nM to 50 
μM) using sheep brain striatum membranes (0.5 mg protein/mL) were performed as 
indicated in Materials and Methods. Binding data were fitted to the two-independent-
site model (eq. 7) or to the two-state dimer receptor model (eq. 5) (solid line) and to the
one-site receptor model (eq. 6) (dotted line). Using the F test, a probability greater than 
95% (p<0.05) was obtained to consider significant better the two-state dimer receptor 
model or the two-independent-site model over the one-site one. Data fit enough well to 
the two-state dimer receptor model (eq. 5) and no significant better fit was obtained 
considering eq. (2). Mean ± SEM values from a representative experiment performed in 
triplicates are shown (see supplementary material for sets of data points).
Figure 2. Competition experiments using a relatively low D1 receptor antagonist 
concentration versus increasing concentrations of the D1 receptor agonist SKF 
81297. Competition experiments of the D1 receptor antagonist [
3H]SCH 23390 (0.8 nM) 
versus increasing concentrations of the D1 receptor agonist SKF 81297 (0.1 nM to 50 
μM) using sheep brain striatum membranes (0.5 mg protein/mL) were performed as 
indicated in Materials and Methods. Binding data were fitted to the two-state dimer 
receptor model (eq. 5) or to the one-site receptor model (eq. 6). Using the F test, no 
significant better fit was obtained by considering more complex models (two-state 













































































dimer receptor model eq. 2 or two independent-site receptor model eq. 7) over the 
simplest one. Mean ± SEM values from a representative experiment performed in 
triplicates are shown.
Figure 3. Competition experiments using D1 receptor antagonist versus increasing 
concentrations of the D1 receptor agonist SKF 38393. Competition experiments of 
0.11 nM (A) or 0.67 nM (B) D1 receptor antagonist [
3H]SCH 23390 versus increasing 
concentrations of the D1 receptor agonist SKF 38393 (0.1 nM to 50 μM) using sheep 
brain striatum membranes (0.27 mg protein/mL) were performed as indicated in 
Materials and Methods. Binding data were fitted to the two-independent-site model (eq. 
7) or to the two-state dimer receptor model (eq. 2) (solid line) and to the one-site 
receptor model (eq. 6) (dotted line). Using the F test, a probability greater than 95% 
(p<0.05) was obtained to consider significant better the two-state dimer receptor model 
or the two-independent-site model over the one-site one. Mean ± SEM values from a 
representative experiment performed in triplicates are shown.
Figure 4. Competition experiments using an adenosine A2A receptor antagonist 
radioligand versus in reasing concentrations of an adenosine A2A receptor agonist.
Competition experiments of the A2A receptor antagonist [
3H]ZM-241385 (3.6 nM in A 
or 0.7 nM in B) versus increasing concentrations of the A2A receptor agonist CGS 
21680 (0.1 nM to 50 μM) using sheep brain striatum membranes (0.4 mg protein/mL) 
were performed as indicated in Materials and Methods. In A, binding data were fitted to 
the two-independent-site model (eq. 7) or to the two-state dimer receptor model (eq. 5) 
(solid line) and to the one-site receptor model (eq. 6) (dotted line). Using the F test, a 













































































probability greater than 95% (p<0.05) was obtained to consider significant better the 
two-state dimer receptor model or the two-independent-site model over the one-site one. 
Data fit enough well to the two-state dimer receptor model (eq. 5) and no significant 
better fit was obtained considering eq. (2). In B, binding data were fitted to the two-state 
dimer receptor model (eq. 5) or to the one-site receptor model (eq. 6). Using the F test, 
no significant better fit was obtained by considering more complex models (two-state 
dimer receptor model eq. 2 or two independent-site receptor model eq. 7) over the 
simplest one. Mean ± SEM values from a representative experiment performed in 
triplicates are shown.
Figure 5 Competition curves simulation. Simulation was performed considering the 
eq. (2) and the following parameter values: RT = 0.3 (pmol/mg protein), KDA1 = 0.47
nM,  KDB1 = 6.5 nM, KDB2 = 26 nM KDAB= 2.5 nM, using different radioligand 
concentrations (A in eq. 2; 0.1, 0,2, 0.3, 0.5, 0.7, 1.0, 1.5, 2.0, 3.0, 5.0 and 10 nM 
bottom to top) and increasing concentrations of the D1 receptor agonist (B in eq. 2; 
0.001 nM to 1 mM)













































































Table 1. Parameter values obtained by fitting data from competition experiments of the 
antagonist [3H]SCH 23390 binding to D1 dopamine receptors with the agonist SKF 
81297 to different models.
1.8 nM [3H]SCH 
23390 
0.8 nM [3H]SCH 
23390
Model Parameters
One-site receptor model R (pmol/mg protein) 0.54 ± 0.07




protein) 0.16 ± 0.02
KDH (nM) 1.7 ± 0.4
RL (pmol/mg 
protein) 0.30 ± 0.04
KDL (nM) 62 ± 10
Two-state dimer receptor 
model
RT (pmol/mg 
protein) 0.34 ± 0.03 0.38 ± 0.03
KDB1 (nM) 7 ± 2 6 ± 1
KDB2 (nM) 28 ± 4 24 ± 5
KDAB (nM) 3 ± 1 1.5 ± 0.7
DCB 0 0
DAB 0.6 ± 0.1 0.8 ± 0.2
B50 (nM) 14 ± 2 12 ± 2
Data are mean ± SEM values from three experiments. R is the maximum specific binding and KD is the 
equilibrium dissociation constant for the competing ligand B (SKF 81297). RH and RL are, respectively, 
the maximum specific binding corresponding to, respectively, high and low affinity sites, and KDH and 
KDL are the equilibrium dissociation constants for, respectively, high and low affinity sites. RT is the total 
amount of receptor dimers, KDB1 and KDB2 are, respectively, the equilibrium dissociation constants of the 
first and second binding of B to the dimer. KDAB is the hybrid equilibrium dissociation constant of B 
binding to a receptor dimer semi-occupied by the A ([3H]SCH 23390). DCB is the dimer cooperativity 
index for the binding of ligand B and DAB is the dimer radioligand/competitor modulation index. B50 is
the concentration providing half saturation for B. 













































































Table 2. Parameter values obtained by fitting data from competition experiments of the 
antagonist [3H]SCH 23390 binding to D1 dopamine receptors with the agonist SKF 
38393
0.67 nM [3H]SCH 
23390 






protein) 0.20 ± 0.01 0.32 ± 0.03
KDH (nM) 1.4 ± 0.3 4.6 ± 0.9
RL (pmol/mg 
protein) 0.56 ± 0.01 0.54 ± 0.03
KDL (nM) 540 ± 40 530 ± 90
Two-state dimer receptor 
model
RT (pmol/mg 
protein) 0.47 ± 0.02 0.48 ± 0.03 
KDB1 (nM) 2.7 ± 0.7 2.7 ± 0.7 
KDB2 (nM) 330 ± 50 430 ± 50 
KDAB (nM) 2.1 ± 0.6 3 ± 1
DCB -1.5 ± 0.2 -1.6 ± 0.2
DAB 0.4± 0.2 0.2± 0.1 
B50 (nM) 30 ± 6 34 ± 6 
Data are mean ± SEM values from three experiments. KDH and KDL are the equilibrium dissociation 
constants for, respectively, high and low affinity sites for the ligand B (SKF 38393). RT is the total 
amount of receptor dimers, KDB1 and KDB2 are, respectively, the equilibrium dissociation constants of the 
first and second binding of B to the dimer. KDAB is the hybrid equilibrium dissociation constant of B 
binding to a receptor dimer semi-occupied by the A ([3H]SCH 23390). DCB is the dimer cooperativity 
index for the binding of ligand B and DAB is the dimer radioligand/competitor modulation index. B50 is
the concentration providing half saturation for B. 













































































Table 3. Parameter values obtained by fitting data from competition experiments of the 
antagonist [3H]ZM-241385 binding to adenosine A2A receptors with the agonist CGS 






One-site receptor model R (pmol/mg protein) 0.9 ± 0.02




protein) 0.7 ± 0.1
KDH (nM) 11 ± 4
RL (pmol/mg 
protein) 0.5 ± 0.1
KDL (nM) 340 ± 140
Two-state dimer receptor 
model
RT (pmol/mg 
protein) 0.68 ± 0.02 0.70 ± 0.01
KDB1 (nM) 31 ± 5 24 ± 6
KDB2 (nM) 124 ± 20 96 ± 24
KDAB (nM) 20 ± 6 27 ± 8
DCB 0 0
DAB 0.5 ± 0.2 0.3 ± 0.2
B50 (nM) 60 ±10 50 ± 10
Data are mean ± SEM values of three experiments. R is the maximum specific binding and KD is the 
equilibrium dissociation constant for the competing ligand B (CGS 21680). RH and RL are, respectively, 
the maximum specific binding corresponding to, respectively, high and low affinity sites, and KDH and 
KDL are the equilibrium dissociation constants for, respectively, high and low affinity sites. RT is the total 
amount of receptor dimers, KDB1 and KDB2 are, respectively, the equilibrium dissociation constants of the 
first and second binding of B to the dimer. KDAB is the hybrid equilibrium dissociation constant of B 
binding to a receptor dimer semi-occupied by the A ([3H]ZM-241385). DCB is the dimer cooperativity 
index for the binding of ligand B and DAB is the dimer radioligand/competitor modulation index. B50 is
the concentration providing half saturation for B. 
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R2  +  B R2B 
k-i
vfR2B = ki [B] [free sites in R2]  = ki [B] 2 [R2]
vdR2B    =  k-i [occupied sites in R2B] = k-i[R2B]
in the equilibrium: ki [B] 2[R2] = k-i [R2B]
k-i/ki  =  2 [B] [R2] / [R2B]  =  2 KDB1
kj
R2A  +  B R2AB
k-j
vfR2AB = kj[B] [free sites in R2A]  = kj [B] [R2A]
vdR2AB    =  k-j [occupied sites in R2AB] = k-j[R2AB]
in the equilibrium: kj [B] [R2A] = k-j [R2AB]
k-j/kj  =  [B] [R2A] / [R2AB]  =  KDAB
when: 
k-i/ki  =   k-j/kj    →      KDAB  =  2 KDB1    (non A / B modulation)
k-i/ki  >   k-j/kj    →      KDAB  >  2 KDB1    (negative A / B modulation)
k-i/ki  <   k-j/kj    →      KDAB  <  2 KDB1    (positive  A / B modulation)
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Data points from competition experiments of 0.8 nM D1 receptor antagonist 













1 - 0.3836 0.4241 0.3283
1 -10.0 0.3718 0.4302 0.3267
1 -9.5 0.3693 0.4353 0.3401
1 -9.0 0.3655 0.4175 0.3235
1 -8.5 0.3584 0.4329 0.3063
1 -8.0 0.3363 0.4222 0.2551
1 -7.5 0.3058 0.4048 0.1935
1 -7.0 0.2253 0.3651 0.1330
1 -6.5 0.1339 0.2628 0.0758
1 -6.0 0.0791 0.1660 0.0484
1 -5.5 0.0605 0.0846 0.0415
1 -5.0 0.0418 0.0544 0.0377
1 -4.3 0.0388 0.0424 0,0353
1 non-specific 0.0380 0.0383 0.0359
2 - 0.3909 0.4317 0.3511
2 -10.0 0.3736 0.4188 0.3267
2 -9.5 0.3598 0.4267 0.3418
2 -9.0 0.3655 0.4145 0.3248
2 -8.5 0.3602 0.4295 0.2965
2 -8.0 0.3400 0.4276 0.2644
2 -7.5 0.3091 0.4081 0.1955
2 -7.0 0,2222 0.3562
2 -6.5 0.1432 0.2665 0.0739
2 -6.0 0.0797 0.1630 0.0499
2 -5.5 0.0655 0.0861 0.0395
2 -5.0 0.0417 0.0537 0.0362
2 -4.3 0.0317 0.0412 0.0351
2 non-specific 0.0372 0.0374 0.0371
3 - 0.3880 0.4139 0.3362
3 -10.0 0.3740 0.4336 0.3335
3 -9.5 0.3651 0.4301 0.3328
3 -9.0 0.3714 0.4328 0.3229
3 -8.5 0.3577 0.3060
3 -8.0 0.3370 0.4121 0.2509
3 -7.5 0.2983 0.3927 0.1963
3 -7.0 0.2247 0.3658 0.1303
3 -6.5 0.1376 0.2687 0.0738
3 -6.0 0.0766 0.1690 0.0488
3 -5.5 0.0652 0.0869 0.0394
3 -5.0 0.0425 0.0554 0.0369












































































3 -4.3 0.0386 0.0429 0.0368
3 non-specific 0.0373 0.0388 0.0359
Data points from competition experiments of 1.8 nM D1 receptor antagonist 













1 - 0.5519 0.4578 0.5679
1 -10.0 0.5424 0.4439 0.5873
1 -9.5 0.5452 0.4369 0.5432
1 -9.0 0.5335 0.4314 0.5304
1 -8.5 0.5114 0.4109 0.4850
1 -8.0 0.4348 0.3777 0.4498
1 -7.5 0.3831 0.3340 0.3997
1 -7.0 0.2857 0.2832 0.3321
1 -6.5 0.1975 0.2158 0.2369
1 -6.0 0.1268 0.1427 0.1521
1 -5.5 0.0942 0.1274 0.1012
1 -5.0 0.0841 0.0947 0.0824
1 -4.3 0.0830 0.0857 0.0826
1 non-specific 0.0849 0.0746
2 - 0.5563 0.4513 0.5777
2 -10.0 0.5517 0.4561 0.5759
2 -9.5 0.5599 0.4410 0.5589
2 -9.0 0.5314 0.4301 0.5202
2 -8.5 0.4959 0.4002 0.4821
2 -8.0 0.4419 0.3690 0.4439
2 -7.5 0.3839 0.3437 0.4111
2 -7.0 0.2951 0.2855
2 -6.5 0.2114 0.2222 0.2403
2 -6.0 0.1296 0.1515 0.1494
2 -5.5 0.0985 0.1194 0.1039
2 -5.0 0.0839 0.0931 0.0828
2 -4.3 0.0830 0.0898 0.0752
2 non-specific 0.0781 0.0843 0.0727
3 - 0.5446 0.4478 0.5622
3 -10.0 0.5528 0.4350 0.5862
3 -9.5 0.5616 0.4330 0.5510
3 -9.0 0.5367 0.4331 0.5454
3 -8.5 0.5124 0.4158 0.5035
3 -8.0 0,4433 0.3687 0.4362
3 -7.5 0.3813 0.3360 0.4188
3 -7.0 0.3016 0.2873 0,3504
3 -6.5 0.1985 0.2193 0.2410












































































3 -6.0 0.1261 0.1468 0.1485
3 -5.5 0.0949 0.1251 0.1027
3 -5.0 0.0843 0.0961 0.0840
3 -4.3 0.0794 0.0872 0.0785
3 non-specific 0.0791 0.0846 0.0745







































































Dimer receptor models can account for changes in the shape of competition curves that 
cannot be explained by monomer receptor models. Radiolabelled antagonist versus agonist 
binding to dopamine D1 receptors
Decreasing
[3H]SCH 23390
concentration
Radioligand Competitor
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